Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
NCT Number: NCT02307409
This study attempts to clarify the pathophysiology of haemostasis and haematopoiesis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these patients. Further research is needed for proper understanding of the influence of sepsis on coagulation disorders in ACLF (Acute on Chronic Liver Failure) patients in particular, to correctly identify the type and optimal quantity of blood product requirement in at risk patients.
Thromboelastography (TEG) /Sonoclot have been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products. Secondly, the study of derangement in coagulopathy after the onset of sepsis is of paramount importance because of increased mortality after the onset of sepsis. In the present study, patients with ACLF (Acute on Chronic Liver Failure) without evidence of sepsis on admission will be included in the study cohort, and will undergo a baseline diagnostic workup as described. They will be followed for development of any signs of infection after hospitalization. Then the effect of sepsis on their coagulation and haematopoietic cellular responses will be assessed. Thus the effect of sepsis on the progression and outcome of patients with ACLF (Acute on Chronic Liver Failure) will be studied.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
New Delhi, National Capital Territory of Delhi, 110070, India
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
Time frame: 0 day, 3 day & 7 day after admission.
Time frame: 0 day, 3 day & 7 day after admission.
Reporting of blood product usage in 7 days of admission as per TEG R time, K time, Maximum amplitude of curve, angle, lysis at 30%.
Time frame: 0 day, 3 day & 7 day after admission.
Reporting of number and site of bleed- skin, mucosa, urine, GI tract, CNS etc.
Time frame: 0 day, 3 day & 7 day after admission.
Correlation of PT/INR with TEG parameters and positive blood or urine culture.
Time frame: 0 day, 3 day & 7 day after admission.
Time frame: 0 day, 3 day & 7 day after admission.
Measurement of reticulocyte count, and peripheral amear- presence of toxic granules.
Institute of Liver and Biliary Sciences, India
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06340269
Acute on Chronic Liver Failure, Acute-On-Chronic Liver Failure
Lyon, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT05124041
Acute on Chronic Liver Failure, Acute-On-Chronic Liver Failure
Chandigarh, Choose Any State/Province, India
View Trial DetailsNCT05059795
Acute on Chronic Liver Failure, Acute-On-Chronic Liver Failure
Chandigarh, India
View Trial DetailsNCT03577938
Acute on Chronic Liver Failure, Acute-On-Chronic Liver Failure
Beijing, Beijing Municipality, China
View Trial Details